Vemurafenib Treatment of Pleomorphic Xanthoastrocytoma in a Child With Down Syndrome

In conclusion, we have shown the safety and efficacy of Vemurafenib in a pediatric patient with DS affected by PXA. Ethics Statement This study was carried out in accordance with the recommendations of the Internal Review Board of the Bambino Gesù Children's Hospital with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Internal Review Board of the Bambino Gesù Children's Hospital. Informed Consent The authors declare that written informed consent was obtained from the patient's parents for publication of this case report. Author Contributions GP, FdB, AM, and FL designed the study. GP, FdB, GC, DV, AntC, and IA cured the collection of the data. FdB, GC, IA, AndC, AM, GSC, TC, and FD-C interpreted and analyzed the data. GP, DV, FdB, and GC drafted the manuscript. FD-C performed immunohistochemistry analysis. EA performed molecular analysis. AM and FL critically revised the manuscript for intellectual content. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We thank the association Heal for the support. References 1. De Graaf G, Buckley F, Skotko BG. Live births, natural losses, and elective terminations with Down syndrome in Massachuset...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research